Latest News

Date Title Topic
28 Jul 2017 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide Endocrine and neuroendocrine tumours
27 Jul 2017 EMA Recommends Granting a Marketing Authorisation for Midostaurin Haematologic malignancies - Anticancer agents & Biologic therapy
26 Jul 2017 Survival After Secondary Primary Malignant Neoplasms Significantly Poorer in Children and AYAs versus Older Patients Epidemiology/Etiology/Cancer Prevention - Cancer in Special Situations
25 Jul 2017 EMA Adopts a New Indication for Pembrolizumab Genitourinary cancers - Cancer Immunology and Immunotherapy
24 Jul 2017 EMA Recommends Granting a Marketing Authorisation for Atezolizumab Genitourinary cancers - Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
21 Jul 2017 ESMO European Integration Fellowship
21 Jul 2017 FDA Grants Regular Approval to Blinatumomab and Expands Indication to Include Philadelphia Chromosome-Positive B-Cell Relapsed or Refractory Precursor ALL Haematologic malignancies - Anticancer agents & Biologic therapy
20 Jul 2017 ESMO 2017 Press Release: ESMO Awards recognise four outstanding oncologists
20 Jul 2017 ESMO 2017 Press Release: Alberto Bardelli Recognised with the ESMO Translational Research Award
20 Jul 2017 Call for Independent Scientific Experts to Join EMA’s Pharmacovigilance Risk Assessment Committee Bioethics, legal and economic issues
19 Jul 2017 How Different Forms of Liquid Biopsies Can Be Exploited to Guide Patient Care? Translational research
19 Jul 2017 FDA Approves Neratinib for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
18 Jul 2017 Patient Guide in Glioma Now Available Also in Dutch
18 Jul 2017 FDA ODAC Recommends Biosimilar Bevacizumab and Trastuzumab Anticancer agents & Biologic therapy
17 Jul 2017 Patient Guide in Bone Sarcoma Now Available Also in Dutch